Clinical trial
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
NCT00243867 · American Regent, Inc., Industry · Completed
Key facts
| NCT number | NCT00243867 |
|---|---|
| Title | Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer |
| Official title | A Phase III, Randomized, Study of Weekly Taxoprexin Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | American Regent, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Taxoprexin, Carboplatin, Paclitaxel |
| Enrollment | 518 |
| Start date | Nov 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Oct 25, 2005 |
| Last update posted | Aug 1, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: